CTS position statement: Pharmacotherapy in patients with COPD—An update

References

• O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2007 update. Can Respir J. 2007;14(Suppl B):5B–32B. doi:10.1155/2007/830570. PMID:17885691.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J. 2008;15(Suppl A):1 A–8A.
   Google Scholar
• From the Global Strategy for the Diagnosis MaPoC, Global Initiative for Chronic Obsctructive Lung Disease (GOLD) 2017. http://goldcopd.org.
   Google Scholar
• Collaborators GCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma,1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691. doi:10.1016/S2213-2600(17)30293-X. PMID:28822787.
   PubMed Web of Science ®Google Scholar
• Organization WH. Noncommunicable diseases progress monitor, 2015, 2015
   Google Scholar
• Bryan S NT. Deaths from Chronic Obstructive Pulmonary Disease in Canada, 1950 to 2011: Statistics Canada. CIHI (Canadain Institute for Health Information); 2015.
   Google Scholar
• Chronic obstructive pulmonary disease in Canadians, 2009 to 2011: Statistic Canada, 2013; http://www.statcan.gc.ca/pub/82-625-x/2012001/article/2011709-eng.htm
   Google Scholar
• Tan WC, Bourbeau J, FitzGerald JM, et al. Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada. Int J Tuberc Lung Dis. 2011;15:1691–1698. doi:10.5588/ijtld.11.0211. PMID:22118181.
   PubMed Web of Science ®Google Scholar
• Information CIfH. Health Indicators. Ottawa: CIHI; 2008, 2008
   Google Scholar
• Hermus G SC, Goldfarb D, Theriault L, Bounajm F. Cost Risk Analysis for Chronic Lung Disease in Canada The Conference Board of Canada, 2012
   Google Scholar
• Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. CMAJ. 2010;182:673–678. doi:10.1503/cmaj.091784. PMID:20371646.
   PubMed Web of Science ®Google Scholar
• Labonte LE, Tan WC, Li PZ, et al. Undiagnosed chronic obstructive pulmonary disease contributes to the burden of health care use. Data from the CanCOLD Study. Am J Respir Crit Care Med. 2016;194:285–298. doi:10.1164/rccm.201509-1795OC. PMID:26836958.
   PubMed Web of Science ®Google Scholar
• Hangaard S, Helle T, Nielsen C, et al. Causes of misdiagnosis of chronic obstructive pulmonary disease: A systematic scoping review. Respir Med. 2017;129:63–84. doi:10.1016/j.rmed.2017.05.015. PMID:28732838.
   PubMed Web of Science ®Google Scholar
• Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Canadian Respiratory J. 2011;18:69–78. doi:10.1155/2011/745047.
   PubMed Web of Science ®Google Scholar
• Sanchis J, Gich I, Pedersen S, et al. Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest. 2016;150:394–406. doi:10.1016/j.chest.2016.03.041. PMID:27060726.
   PubMed Web of Science ®Google Scholar
• Camp PG, Hernandez P, Bourbeau J, et al. Pulmonary rehabilitation in Canada: A report from the Canadian Thoracic Society COPD Clinical Assembly. Can Respir J. 2015;22:147–152. doi:10.1155/2015/369851. PMID:25848802.
   PubMed Web of Science ®Google Scholar
• Hernandez P, Balter M, Bourbeau J, et al. Living with chronic obstructive pulmonary disease: a survey of patients' knowledge and attitudes. Respir Med. 2009;103:1004–1012. doi:10.1016/j.rmed.2009.01.018. PMID:19269150.
   PubMed Web of Science ®Google Scholar
• Grace SL, Chessex C, Arthur H, et al. Systematizing inpatient referral to cardiac rehabilitation 2010: Canadian Association of Cardiac Rehabilitation and Canadian Cardiovascular Society joint position paper endorsed by the Cardiac Care Network of Ontario. Can J Cardiol. 2011;27:192–199. doi:10.1016/j.cjca.2010.12.007. PMID:21459268.
   PubMedGoogle Scholar
• Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894–942. doi:10.1378/chest.14-1676. PMID:25321320.
   PubMed Web of Science ®Google Scholar
• Marciniuk DD, Brooks D, Butcher S, et al. Optimizing pulmonary rehabilitation in chronic obstructive pulmonary disease–practical issues: a Canadian Thoracic Society Clinical Practice Guideline. Can Respir J. 2010;17:159–168. doi:10.1155/2010/425975. PMID:20808973.
   PubMed Web of Science ®Google Scholar
• Marciniuk DD, Hernandez P, Balter M, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline.[Erratum appears in Can Respir J. 2012 Jul-Aug;19(4):272]. Canadian Respiratory Journal. 2012;19:109–116. doi:10.1155/2012/920918. PMID:22536580.
   PubMed Web of Science ®Google Scholar
• Gupta S, Bhattacharyya OK, Brouwers MC, et al. Canadian Thoracic Society: Presenting a new process for clinical practice guideline production. Can Respir J. 2009;16:e62–68. doi:10.1155/2009/397818. PMID:20011719.
   PubMedGoogle Scholar
• Hsu CC SB. The Delphi technique: making sense of consensus. Practical Assessment Research & Evaluation. 2007;12:1–8
   Google Scholar
• Lewis SZ, Diekemper R, Ornelas J, et al. Methodologies for the development of CHEST guidelines and expert panel reports. Chest. 2014;146:182–192. doi:10.1378/chest.14-0824. PMID:25010961.
   PubMedGoogle Scholar
• O'Donnell DE, Laveneziana P, Webb K, et al. Chronic obstructive pulmonary disease: clinical integrative physiology. Clin Chest Med. 2014;35:51–69. doi:10.1016/j.ccm.2013.09.008. PMID:24507837.
   PubMed Web of Science ®Google Scholar
• Gupta N, Pinto LM, Morogan A, et al. The COPD assessment test: a systematic review. Eur Respir J. 2014;44:873–884. doi:10.1183/09031936.00025214. PMID:24993906.
   PubMed Web of Science ®Google Scholar
• Bedard ME, Brouillard C, Pepin V, et al. Tiotropium improves walking endurance in COPD. Eur Resp J. 2012;39:265–271. doi:10.1183/09031936.00059511.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Singh D, Di Scala L, et al. Once-daily NVA237 improves exercise tolerance from the first dose in patients with COPD: the GLOW3 trial. Inter J Copd. 2012;7:503–513. doi:10.2147/COPD.S32451.
   Google Scholar
• Beeh KM, Wagner F, Khindri S, et al. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD. Copd J Chro Obstr Pulm Dise. 2011;8:340–345. doi:10.3109/15412555.2011.594464.
   Web of Science ®Google Scholar
• Beeh KM, Watz H, Puente-Maestu L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm Medi. 2014;14:209. doi:10.1186/1471-2466-14-209. PMID:25539654.
   PubMed Web of Science ®Google Scholar
• Brouillard C, Pepin V, Milot J, et al. Endurance shuttle walking test: responsiveness to salmeterol in COPD. Eur Resp J. 2008;31:579–584. doi:10.1183/09031936.00119007.
   PubMed Web of Science ®Google Scholar
• Cooper CB, Celli BR, Jardim JR, et al. Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: a randomized trial. Chest. 2013;144:490–497. doi:10.1378/chest.12-2613. PMID:23558890.
   PubMed Web of Science ®Google Scholar
• Gotfried MH, Kerwin EM, Lawrence D, et al. Efficacy of indacaterol 75 mug once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies. C J Chro Obstr Pulm Dise. 2012;9:629–636. doi:10.3109/15412555.2012.729623.
   Web of Science ®Google Scholar
• Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials. BMC Pulm Medi. 2013;13:26. doi:10.1186/1471-2466-13-26. PMID:23617268.
   PubMed Web of Science ®Google Scholar
• Jiang FM, Liang ZA, Zheng QL, et al. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review. Lung. 2013;191:135–146. doi:10.1007/s00408-012-9444-2. PMID:23306410.
   PubMedGoogle Scholar
• Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Resp J. 2012;40:830–836. doi:10.1183/09031936.00225511.
   PubMed Web of Science ®Google Scholar
• Kaplan A. Effect of tiotropium on quality of life in COPD: A systematic review. Prim Care Resp J. 2010;19:315–325. doi:10.4104/pcrj.2010.00067.
   PubMedGoogle Scholar
• Kerwin EM, D'Urzo AD, Gelb AF, et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). Copd J Chro Obstr Pulm Dise. 2012;9:90–101. doi:10.3109/15412555.2012.661492.
   Web of Science ®Google Scholar
• Kerwin EM, Gotfried MH, Lawrence D, et al. Efficacy and tolerability of indacaterol 75 mug once daily in patients aged >40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies. Clin Therap. 2011;33:1974–1984. doi:10.1016/j.clinthera.2011.11.009. PMID:22177371.
   PubMed Web of Science ®Google Scholar
• Kinoshita M, Lee SH, Hang LW, et al. Efficacy and safety of indacaterol 150 and 300 micro g in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study. Respirology. 2012;17:379–389. doi:10.1111/j.1440-1843.2011.02107.x. PMID:22122202.
   PubMed Web of Science ®Google Scholar
• Maltais F, Celli B, Casaburi R, et al. Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Resp Medi. 2011;105:580–587. doi:10.1016/j.rmed.2010.11.019. PMID:21183326.
   PubMed Web of Science ®Google Scholar
• Mroz RM, Minarowski L, Chyczewska E. Indacaterol add-on therapy improves lung function, exercise capacity and life quality of COPD patients. Adva Experi Medi Biol. 2013;756:23–28. doi:10.1007/978-94-007-4549-0_4.
   Google Scholar
• O'Donnell DE, Casaburi R, Vincken W, et al. Effect of indacaterol on exercise endurance and lung hyperinflation in COPD. Respir Medi. 2011;105:1030–1036. doi:10.1016/j.rmed.2011.03.014. PMID:21498063.
   PubMed Web of Science ®Google Scholar
• Rennard SI, Scanlon PD, Ferguson GT, et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients. Clin Drug Invest. 2013;33:893–904. doi:10.1007/s40261-013-0138-1. PMID:24085591.
   PubMed Web of Science ®Google Scholar
• Santus P, Radovanovic D, Di Marco F, et al. Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm Pharm Therap. 2015;35:42–49. doi:10.1016/j.pupt.2015.11.001.
   PubMed Web of Science ®Google Scholar
• Satake M, Takahashi H, Sugawara K, et al. Inhibitory effect of procaterol on exercise dynamic lung hyperinflation during the 6-min walk test in stable patients with chronic obstructive pulmonary disease. Arzneim-Forsch. 2011;61:8–13. doi:10.1055/s-0031-1296162.
   Google Scholar
• Trivedi R, Richard N, Mehta R, et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study.[Erratum appears in Eur Respir J. 2014 Aug;44(2):555 Note: Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text]. Eur Respir J.2014;43:72–81. doi:10.1183/09031936.00033213.
   PubMed Web of Science ®Google Scholar
• Yao W, Wang C, Zhong N, et al. Effect of once-daily indacaterol in a predominantly Chinese population with chronic obstructive pulmonary disease: a 26-week Asia-Pacific study. Respirology. 2014;19:231–238. doi:10.1111/resp.12211. PMID:24383720.
   PubMed Web of Science ®Google Scholar
• Bogdan MA, Aizawa H, Fukuchi Y, et al. Efficacy and safety of inhaled formoterol 4.5 and 9 mug twice daily in Japanese and European COPD patients: phase III study results. BMC Pulm Medi. 2011;11:51. doi:10.1186/1471-2466-11-51. PMID:22085439.
   PubMedGoogle Scholar
• Braido F, Baiardini I, Cazzola M, et al. Long-acting bronchodilators improve health related quality of life in patients with COPD. Respir Med. 2013;107:1465–1480. doi:10.1016/j.rmed.2013.08.007. PMID:24001507.
   PubMed Web of Science ®Google Scholar
• Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015:CD009552 PMID:26391969.
   PubMedGoogle Scholar
• Geake JB, Dabscheck EJ, Wood-Baker R, et al. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta(2)-agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;1:CD010139 PMID:25575340.
   PubMedGoogle Scholar
• Gross NJ, Nelson HS, Lapidus RJ, et al. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008;102:189–197. doi:10.1016/j.rmed.2007.10.007. PMID:18363201.
   PubMed Web of Science ®Google Scholar
• Jones PW, Mahler DA, Gale R, et al. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD. Respir Med. 2011;105:892–899. doi:10.1016/j.rmed.2011.02.013. PMID:21397482.
   PubMedGoogle Scholar
• Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012:CD008989 PMID:22513969.
   PubMedGoogle Scholar
• Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013:CD010177 PMID:24127118.
   PubMedGoogle Scholar
• Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered via Respimat versus placebo and formoterol twice daily in patients with GOLD 2–4 COPD: results from two replicate 48-week studies. Intern J Copd. 2014;9:697–714. doi:10.2147/COPD.S62502.
   Google Scholar
• Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273–279. doi:10.1183/09031936.00045810. PMID:20693243.
   PubMed Web of Science ®Google Scholar
• Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014:CD010509 PMID:25234126.
   PubMedGoogle Scholar
• Park J, Lee JS, Rhee C, et al. Effect of Indacaterol on Cough and Phlegm in Chronic Obstructive Pulmonary Disease Patients: A Meta-Analysis of Five Randomized Controlled Trials. J Korean Med Sci. 2015;30:1453–1458. doi:10.3346/jkms.2015.30.10.1453. PMID:26425042.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Korn S, Beier J, et al. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study. Respir Med. 2014;108:584–592. doi:10.1016/j.rmed.2014.01.006. PMID:24534204.
   PubMed Web of Science ®Google Scholar
• Berton DC, Reis M, Siqueira AC, et al. Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD. Respir Med. 2010;104:1288–1296. doi:10.1016/j.rmed.2010.05.017. PMID:20580216.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Ciaprini C, Puxeddu E, et al. Olodaterol + tiotropium bromide for the treatment of COPD. Expert Rev Respir Med. 2016;6:1–8 PMID:26894830.
   PubMedGoogle Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145:981–991. doi:10.1378/chest.13-1579. PMID:24385182.
   PubMed Web of Science ®Google Scholar
• Chen X, May B, Di YM, et al. Oral Chinese herbal medicine combined with pharmacotherapy for stable COPD: a systematic review of effect on BODE index and six minute walk test. PLoS ONE [Electronic Resource]. 2014;9:e91830. doi:10.1371/journal.pone.0091830.
   Google Scholar
• Jayaram L, Wong C, McAuley S, et al. Combined therapy with tiotropium and formoterol in chronic obstructive pulmonary disease: effect on the 6-minute walk test. Copd J Chro Obstr Pulm Dise. 2013;10:466–472. doi:10.3109/15412555.2013.771162.
   Web of Science ®Google Scholar
• Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J. 2014;43:1599–1609. doi:10.1183/09031936.00124013. PMID:24176997.
   PubMed Web of Science ®Google Scholar
• Maltais F, Singh S, Donald AC, et al. Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. [Erratum appears in Ther Adv Respir Dis. 2016 Jun;10(3):289;PMID:27255756]. Therap Adva Respir Dise. 2014;8:169–181. doi:10.1177/1753465814559209. PMID:25452426.
   PubMed Web of Science ®Google Scholar
• Rodrigo GJ, Neffen H. Comparison of indacaterol with tiotropium or twice-daily long-acting beta -agonists for stable COPD: a systematic review. Chest. 2012;142:1104–1110. doi:10.1378/chest.11-2252. PMID:22383666.
   PubMed Web of Science ®Google Scholar
• Vincken W, Aumann J, Chen H, et al. Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study. Inter J Copd. 2014;9:215–228. doi:10.2147/COPD.S51592.
   Google Scholar
• Wang L, Zhai CJ, Liu Y, et al. Umeclidinium plus vilanterol versus Placebo, Umeclidinium, or Vilanterol Monotherapies for chronic obstructive pulmonary disease: A meta-analysis of randomized controlled trials. Clin Drug Investi. 2016;36:865–875. doi:10.1007/s40261-016-0449-0. PMID:27539612.
   PubMed Web of Science ®Google Scholar
• Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4).[Erratum appears in Eur Respir J. 2015 Jun;45(6):1763;PMID: 26028626]. Eur Respir J 2015;45:969–979. doi:10.1183/09031936.00136014. PMID:25573406.
   PubMed Web of Science ®Google Scholar
• Calzetta L, Rogliani P, Matera MG, et al. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest 2016;149:1181–1196. doi:10.1016/j.chest.2016.02.646. PMID:26923629.
   PubMed Web of Science ®Google Scholar
• Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015:CD008989 PMID:26490945.
   PubMedGoogle Scholar
• Maleki-Yazdi MR, Kaelin T, Richard N, et al. Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial. Respir Med. 2014;108:1752–1760. doi:10.1016/j.rmed.2014.10.002. PMID:25458157.
   PubMed Web of Science ®Google Scholar
• ZuWallack R, Allen L, Hernandez G, et al. Efficacy and safety of combining olodaterol Respimat() and tiotropium HandiHaler() in patients with COPD: results of two randomized, double-blind, active-controlled studies. Inter J Copd. 2014;9:1133–1144. doi:10.2147/COPD.S72482.
   Google Scholar
• Watz H, Krippner F, Kirsten A, et al. Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease–a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Medi. 2014;14:158. doi:10.1186/1471-2466-14-158. PMID:25280934.
   PubMedGoogle Scholar
• Watz H, Mailander C, Baier M, et al. Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (The MOVE Study). BMC Pulm Medi. 2016;16:95. doi:10.1186/s12890-016-0256-7. PMID:27301417.
   PubMedGoogle Scholar
• Watz HTT, Beeh KM, Garcia-Aymerich J, Paggiaro P, Molins E, Notari M, Zapata A, Jarreta D, Garcia Gil E. ACTIVATE: the effect of aclidinium/formoterol on hyperinflation, exercise capacity, and physical activity in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:2545–2558.
   Google Scholar
• Troosters T, Sciurba FC, Decramer M, et al. Tiotropium in patients with moderate COPD naive to maintenance therapy: a randomised placebo-controlled trial. NPJ Prim Care Respir Med. 2014;24:14003. doi:10.1038/npjpcrm.2014.3. PMID:24841833.
   PubMed Web of Science ®Google Scholar
• Horita N, Goto A, Shibata Y, et al. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2017;2:CD012066 PMID:28185242.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Ohtawa J, Akitsu K. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair() in chronic obstructive pulmonary disease. Pulm Pharmacol Therap. 2015;30:128–133. doi:10.1016/j.pupt.2014.08.002.
   PubMed Web of Science ®Google Scholar
• Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545–555. doi:10.7326/0003-4819-146-8-200704170-00152. PMID:17310045.
   PubMed Web of Science ®Google Scholar
• Karner C, Cates CJ. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011:CD008532 PMID:21412920.
   PubMedGoogle Scholar
• Kawayama T, Hoshino T, Ichiki M, et al. Effect of add-on therapy of tiotropium in COPD treated with theophylline. Inter J Copd. 2008;3:137–147. doi:10.2147/COPD.S2103.
   Google Scholar
• Voduc N, Alvarez GG, Amjadi K, et al. Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: A pilot study. Inter J Copd. 2012;7:245–252. doi:10.2147/COPD.S29990.
   Google Scholar
• Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703. doi:10.1016/S0140-6736(09)61252-6. PMID:19716961.
   PubMed Web of Science ®Google Scholar
• O'Donnell DE, Bredenbroker D, Brose M, et al. Physiological effects of roflumilast at rest and during exercise in COPD. Eur Respir J. 2012;39:1104–1112. doi:10.1183/09031936.00096511. PMID:21965226.
   PubMed Web of Science ®Google Scholar
• Pan L, Guo YZ, Zhang B, et al. Does roflumilast improve dyspnea in patients with chronic obstructive pulmonary disease? A meta-analysis. J Thor Dise. 2013;5:422–429 PMID:23991297.
   PubMed Web of Science ®Google Scholar
• Johnson K, McEvoy CE, Naqvi S, et al. High-dose oral N-acetylcysteine fails to improve respiratory health status in patients with chronic obstructive pulmonary disease and chronic bronchitis: a randomized, placebo-controlled trial. Inter J Copd. 2016;11:799–807.
   Google Scholar
• Lee TM, Chen CC, Shen HN, et al. Effects of pravastatin on functional capacity in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Clin Sci. 2009;116:497–505. doi:10.1042/CS20080241. PMID:18831711.
   PubMed Web of Science ®Google Scholar
• Maneechotesuwan K, Wongkajornsilp A, Adcock IM, et al. Simvastatin Suppresses Airway IL-17 and Upregulates IL-10 in Patients With Stable COPD. Chest. 2015;148:1164–1176. doi:10.1378/chest.14-3138. PMID:26043025.
   PubMed Web of Science ®Google Scholar
• Mroz RM, Lisowski P, Tycinska A, et al. Anti-inflammatory effects of atorvastatin treatment in chronic obstructive pulmonary disease. A controlled pilot study. J Physiol Pharmacol. 2015;66:111–128
   PubMed Web of Science ®Google Scholar
• Daga MK, Khan NA, Malhotra V, et al. Study of body composition, lung function, and quality of life following use of anabolic steroids in patients with chronic obstructive pulmonary disease. Nutr Clin Pract. 2014;29:238–245. doi:10.1177/0884533614522832. PMID:24552826.
   PubMedGoogle Scholar
• Pan L, Wang M, Xie X, et al. Effects of anabolic steroids on chronic obstructive pulmonary disease: a meta-analysis of randomised controlled trials. PLoS ONE [Electronic Resource]. 2014;9:e84855. doi:10.1371/journal.pone.0084855.
   Google Scholar
• An X, Zhang AL, May BH, et al. Oral Chinese herbal medicine for improvement of quality of life in patients with stable chronic obstructive pulmonary disease: a systematic review. J Altern Complem Medi. 2012;18:731–743. doi:10.1089/acm.2011.0389.
   Google Scholar
• An X, Zhang AL, Yang AW, et al. Oral ginseng formulae for stable chronic obstructive pulmonary disease: a systematic review. Respir Med. 2011;105:165–176. doi:10.1016/j.rmed.2010.11.007. PMID:21146973.
   PubMed Web of Science ®Google Scholar
• Liu J, Gao F, Li Z. Effect of yiqibushenhuoxue decoction on chronic obstructive pulmonary disease measured by St. George's respiratory disease questionnaire scores and forced expiratory volume. J Tradi Chin Medi. 2014;34:445–449. doi:10.1016/S0254-6272(15)30044-3.
   Google Scholar
• Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J. 2013;42:982–992. doi:10.1183/09031936.00176312. PMID:23429918.
   PubMed Web of Science ®Google Scholar
• Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. The Lanc Resp Medi. 2014;2:293–300. doi:10.1016/S2213-2600(14)70013-X. PMID:24717626.
   PubMed Web of Science ®Google Scholar
• Holverda S, Rietema H, Bogaard HJ, et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulmo Pharmacol Therape. 2008;21:558–564. doi:10.1016/j.pupt.2008.01.012.
   PubMed Web of Science ®Google Scholar
• Rao RS, Singh S, Sharma BB, et al. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Ind J Chest Dise Alli Sci. 2011;53:81–85
   PubMedGoogle Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–1138. doi:10.1056/NEJMoa0909883. PMID:20843247.
   PubMed Web of Science ®Google Scholar
• D'Urzo A, Kerwin E, Overend T, et al. Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies. Curr Med Res Opin. 2014;30:493–508. doi:10.1185/03007995.2013.858618. PMID:24156566.
   PubMed Web of Science ®Google Scholar
• Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012:CD009285 PMID:22786525.
   PubMedGoogle Scholar
• Lee SH, Lee J, Yoo KH, et al. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population. Respirology. 2015;20:1222–1228. doi:10.1111/resp.12641. PMID:26370136.
   PubMedGoogle Scholar
• Matera MG, Rogliani P, Cazzola M. Indacaterol for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2015;16:107–115. doi:10.1517/14656566.2015.983076. PMID:25418284.
   PubMed Web of Science ®Google Scholar
• Oba Y, Lone NA. Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression. Ther Adv Respir Dis. 2015;9:3–15. doi:10.1177/1753465814565624. PMID:25586493.
   PubMed Web of Science ®Google Scholar
• Pleasants RA, Wang T, Gao J, et al. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis. Drugs. 2016;76:343–361. doi:10.1007/s40265-015-0532-5. PMID:26755180.
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017;49.
   Google Scholar
• Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res. 2015;16:92. doi:10.1186/s12931-015-0250-2. PMID:26233481.
   PubMed Web of Science ®Google Scholar
• Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2:472–486. doi:10.1016/S2213-2600(14)70065-7. PMID:24835833.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Singh D, Munzu C, et al. Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials. Respir Med. 2016;112:65–74. doi:10.1016/j.rmed.2016.01.001. PMID:26797016.
   PubMed Web of Science ®Google Scholar
• Horita N, Kaneko T. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan. Int J Chron Obstruct Pulmon Dis. 2015;10:813–822. doi:10.2147/COPD.S56067. PMID:25960646.
   PubMed Web of Science ®Google Scholar
• Kalberg C, O'Dell D, Galkin D, et al. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial. Drugs R D. 2016;16:217–227. doi:10.1007/s40268-016-0131-2. PMID:27028749.
   PubMedGoogle Scholar
• Oba Y, Sarva ST, Dias S. Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis. Thorax. 2016;71:15–25. doi:10.1136/thoraxjnl-2014-206732. PMID:26490732.
   PubMed Web of Science ®Google Scholar
• Schlueter M, Gonzalez-Rojas N, Baldwin M, et al. Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting beta2-agonists: a systematic review and network meta-analysis. Ther Adv Respir Dis. 2016;10:89–104. doi:10.1177/1753465815624612. PMID:26746383.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Dahl R, Buhl R, et al. Pooled safety analysis of the fixed-dose combination of indacaterol and glycopyrronium (QVA149), its monocomponents, and tiotropium versus placebo in COPD patients. Respir Med. 2014;108:1498–1507. doi:10.1016/j.rmed.2014.07.011. PMID:25135743.
   PubMed Web of Science ®Google Scholar
• GINA/GOLD. Diagnosis of diseases of Chronic Airflow Limitation: asthma, COPD and asthma-COPD Overlap Syndrome (ACOS), 2015
   Google Scholar
• Oba Y, Lone NA. Comparative efficacy of inhaled corticosteroid and long-acting beta agonist combinations in preventing COPD exacerbations: a Bayesian network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:469–479. doi:10.2147/COPD.S48492. PMID:24872685.
   PubMed Web of Science ®Google Scholar
• Ohar JA, Crater GD, Emmett A, et al. Fluticasone propionate/salmeterol 250/50 mug versus salmeterol 50 mug after chronic obstructive pulmonary disease exacerbation. Respir Res. 2014;15:105. doi:10.1186/s12931-014-0105-2. PMID:25248764.
   PubMed Web of Science ®Google Scholar
• Singh D, Nicolini G, Bindi E, et al. Extrafine beclomethasone/formoterol compared to fluticasone/salmeterol combination therapy in COPD. BMC Pulm Med. 2014;14:43. doi:10.1186/1471-2466-14-43. PMID:24621109.
   PubMed Web of Science ®Google Scholar
• Stynes G, Svedsater H, Wex J, et al. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD – mixed treatment comparisons of clinical efficacy. Respir Res. 2015;16:25. doi:10.1186/s12931-015-0184-8. PMID:25849223.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med. 2016;375:1253–1260. doi:10.1056/NEJMoa1608033. PMID:27593504.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Singh D, Vestbo J, et al. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Respir Med. 2014;108:1153–1162. doi:10.1016/j.rmed.2014.05.013. PMID:24953015.
   PubMed Web of Science ®Google Scholar
• Hedeker DG, Waternaux RD. C. Sample size estimation for longitudinal designs with attrition: Comparing time-related contrasts between two groups. J Educ Behav Stat. 1999;24:70–93. doi:10.3102/10769986024001070.
   Web of Science ®Google Scholar
• Horita N, Miyazawa N, Morita S, et al. Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study. Respir Res. 2013;14:62. doi:10.1186/1465-9921-14-62. PMID:23725215.
   PubMedGoogle Scholar
• Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285–1294. doi:10.1056/NEJMoa1407154. PMID:25196117.
   PubMed Web of Science ®Google Scholar
• Oba Y, Chandran AV, Devasahayam JV. Long-acting Muscarinic Antagonist Versus Inhaled Corticosteroid when Added to Long-acting beta-agonist for COPD: A Meta-analysis. COPD. 2016;13:677–685. doi:10.3109/15412555.2016.1170799. PMID:27148815.
   PubMedGoogle Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374:2222–2234. doi:10.1056/NEJMoa1516385. PMID:27181606.
   PubMed Web of Science ®Google Scholar
• Zhong N, Wang C, Zhou X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:1015–1026 PMID:26082625.
   PubMed Web of Science ®Google Scholar
• Kwak MS, Kim E, Jang EJ, et al. The efficacy and safety of triple inhaled treatment in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis using Bayesian methods. Int J Chron Obstruct Pulmon Dis. 2015;10:2365–2376 PMID:26604734.
   PubMed Web of Science ®Google Scholar
• Liu Y, Shi H, Sun X, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in COPD: a meta-analysis. Eur J Intern Med. 2014;25:491–495. doi:10.1016/j.ejim.2014.04.007. PMID:24816076.
   PubMedGoogle Scholar
• Rojas-Reyes MX, Garcia Morales OM, Dennis RJ, et al. Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016:CD008532 PMID:27271056.
   PubMedGoogle Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389:1919–1929. doi:10.1016/S0140-6736(17)30188-5. PMID:28385353.
   PubMed Web of Science ®Google Scholar
• Carone M, Donner CF, Jones PW. Health Status measurement: an increasingly important outcome evaluation in COPD patients. Monaldi Arch Chest Dis. 2001;56:297–298 PMID:11770207.
   PubMedGoogle Scholar
• Hanania NA, Calverley PM, Dransfield MT, et al. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014;108:366–375. doi:10.1016/j.rmed.2013.09.018. PMID:24120253.
   PubMed Web of Science ®Google Scholar
• Luo J, Wang K, Liu D, et al. Can roflumilast, a phosphodiesterase-4 inhibitor, improve clinical outcomes in patients with moderate-to-severe chronic obstructive pulmonary disease? A meta-analysis. Respir Res. 2016;17:18. doi:10.1186/s12931-016-0330-y. PMID:26887407.
   PubMed Web of Science ®Google Scholar
• Luo P, Li S, Chen Y, et al. Efficiency and safety of roflumilast combined with long-acting bronchodilators on moderate-to-severe stable chronic obstructive pulmonary disease patients: a meta-analysis. J Thorac Dis. 2016;8:2638–2645. doi:10.21037/jtd.2016.09.12. PMID:27747018.
   PubMedGoogle Scholar
• Martinez FJ, Calverley PM, Goehring UM, et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. 2015;385:857–866. doi:10.1016/S0140-6736(14)62410-7. PMID:25684586.
   PubMed Web of Science ®Google Scholar
• Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Pulm Pharmacol Ther. 2014;27:83–89. doi:10.1016/j.pupt.2013.04.004. PMID:23624309.
   PubMed Web of Science ®Google Scholar
• Ayfer Aytemur Z, Baysak A, Ozdemir O, et al. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum. Wien Klin Wochenschr. 2015;127:256–261. doi:10.1007/s00508-014-0692-4. PMID:25595117.
   PubMedGoogle Scholar
• Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015;24:451–461. doi:10.1183/16000617.00002215. PMID:26324807.
   PubMed Web of Science ®Google Scholar
• Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015:CD001287 PMID:26222376.
   PubMedGoogle Scholar
• Shen Y, Cai W, Lei S, et al. Effect of high/low dose N-acetylcysteine on chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD. 2014;11:351–358 PMID:24378052.
   PubMedGoogle Scholar
• Tse HN, Raiteri L, Wong KY, et al. Benefits of high-dose N-acetylcysteine to exacerbation-prone patients with COPD. Chest. 2014;146:611–623. doi:10.1378/chest.13-2784. PMID:24833327.
   PubMed Web of Science ®Google Scholar
• Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2:187–194. doi:10.1016/S2213-2600(13)70286-8. PMID:24621680.
   PubMed Web of Science ®Google Scholar
• Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189:1503–1508. doi:10.1164/rccm.201402-0207OC. PMID:24779680.
   PubMed Web of Science ®Google Scholar
• Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10:e0121257. doi:10.1371/journal.pone.0121257. PMID:25812085.
   PubMed Web of Science ®Google Scholar
• Simpson JL, Powell H, Baines KJ, et al. The effect of azithromycin in adults with stable neutrophilic COPD: a double blind randomised, placebo controlled trial. PLoS One. 2014;9:e105609. doi:10.1371/journal.pone.0105609. PMID:25148049.
   PubMed Web of Science ®Google Scholar
• Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2:361–368. doi:10.1016/S2213-2600(14)70019-0. PMID:24746000.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1:210–223. doi:10.1016/S2213-2600(13)70040-7. PMID:24429127.
   PubMed Web of Science ®Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. doi:10.1056/NEJMoa063070. PMID:17314337.
   PubMed Web of Science ®Google Scholar
• Suissa S, Patenaude V, Lapi F, et al. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029–1036. doi:10.1136/thoraxjnl-2012-202872. PMID:24130228.
   PubMed Web of Science ®Google Scholar
• Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3:435–442. doi:10.1016/S2213-2600(15)00106-X. PMID:25878028.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. The Lancet Respir Medi. 2016;4:731–741. doi:10.1016/S2213-2600(16)30148-5. PMID:27460163.
   PubMed Web of Science ®Google Scholar
• Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: A Biomarker of Response to Extrafine Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2015;192:523–525. doi:10.1164/rccm.201502-0235LE. PMID:26051430.
   PubMed Web of Science ®Google Scholar
• Roche N, Chapman KR, Vogelmeier CF, et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive Pulmonary Disease Treatment. Data from the FLAME Trial. Am J Respir Crit Care Med. 2017;195:1189–1197. doi:10.1164/rccm.201701-0193OC.
   PubMed Web of Science ®Google Scholar
• Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4:390–398. doi:10.1016/S2213-2600(16)00100-4. PMID:27066739.
   PubMed Web of Science ®Google Scholar
• Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood Eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen General Population Study. Am J Respir Crit Care Med. 2016;193:965–974. doi:10.1164/rccm.201509-1869OC. PMID:26641631.
   PubMed Web of Science ®Google Scholar
• Landis SH, Suruki R, Hilton E, et al. Stability of Blood Eosinophil Count in Patients with COPD in the UK Clinical Practice Research Datalink. COPD. 2017;14:382–388. doi:10.1080/15412555.2017.1313827. PMID:28569614.
   PubMedGoogle Scholar
• Fletcher CM, Pride NB. Definitions of emphysema, chronic bronchitis, asthma, and airflow obstruction: 25 years on from the Ciba symposium. Thorax. 1984;39:81–85. doi:10.1136/thx.39.2.81. PMID:6701830.
   PubMed Web of Science ®Google Scholar
• Kraft M. Asthma and chronic obstructive pulmonary disease exhibit common origins in any country! Am J Respir Crit Care Med. 2006;174:238–240; discussion 243–234. doi:10.1164/rccm.2604007.
   Google Scholar
• Pride N. Smoking, allergy and airways obstruction: revival of the ‘Dutch hypothesis’. Clin Allergy. 1986;16:3–6. doi:10.1111/j.1365-2222.1986.tb01946.x. PMID:3485478.
   PubMedGoogle Scholar
• Soler-Cataluna JJ, Cosio B, Izquierdo JL, et al. Consensus document on the overlap phenotype COPD-asthma in COPD. Arch Bronconeumol. 2012;48:331–337. doi:10.1016/j.arbr.2012.06.017. PMID:22341911.
   PubMed Web of Science ®Google Scholar
• Sin DD, Miravitlles M, Mannino DM, et al. What is asthma-COPD overlap syndrome? Towards a consensus definition from a round table discussion. Eur Respir J. 2016;48:664–673. doi:10.1183/13993003.00436-2016. PMID:27338195.
   PubMed Web of Science ®Google Scholar
• Araujo D, Padrao E, Morais-Almeida M, et al. Asthma-chronic obstructive pulmonary disease overlap syndrome – Literature review and contributions towards a Portuguese consensus. Rev Port Pneumol (2006) 2017;23:90–99 PMID:28089081.
   PubMed Web of Science ®Google Scholar
• Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? Thorax. 2009;64:728–735. doi:10.1136/thx.2008.108027. PMID:19638566.
   PubMed Web of Science ®Google Scholar
• de Marco R, Pesce G, Marcon A, et al. The coexistence of asthma and chronic obstructive pulmonary disease (COPD): prevalence and risk factors in young, middle-aged and elderly people from the general population. PLoS One. 2013;8:e62985. doi:10.1371/journal.pone.0062985. PMID:23675448.
   PubMedGoogle Scholar
• Nielsen M, Barnes CB, Ulrik CS. Clinical characteristics of the asthma-COPD overlap syndrome–a systematic review. Int J Chron Obstruct Pulmon Dis. 2015;10:1443–1454 PMID:26251584.
   PubMed Web of Science ®Google Scholar
• Alshabanat A, Zafari Z, Albanyan O, et al. Asthma and COPD Overlap Syndrome (ACOS): A Systematic Review and Meta Analysis. PLoS One. 2015;10:e0136065. doi:10.1371/journal.pone.0136065. PMID:26336076.
   PubMed Web of Science ®Google Scholar
• Cosio BG, Soriano JB, Lopez-Campos JL, et al. Defining the Asthma-COPD Overlap Syndrome in a COPD Cohort. Chest. 2016;149:45–52. doi:10.1378/chest.15-1055. PMID:26291753.
   PubMed Web of Science ®Google Scholar
• Tamada T, Sugiura H, Takahashi T, et al. Biomarker-based detection of asthma-COPD overlap syndrome in COPD populations. Int J Chron Obstruct Pulmon Dis. 2015;10:2169–2176. doi:10.2147/COPD.S88274. PMID:26491283.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Lettis S, Locantore N, et al. Blood eosinophils and inhaled corticosteroid/long-acting beta-2 agonist efficacy in COPD. Thorax. 2016;71:118–125. doi:10.1136/thoraxjnl-2015-207021. PMID:26585525.
   PubMed Web of Science ®Google Scholar
• Hines KL, Peebles RS, Jr. Management of the Asthma-COPD Overlap Syndrome (ACOS): a Review of the Evidence. Curr Allergy Asthma Rep. 2017;17:15. doi:10.1007/s11882-017-0683-4. PMID:28283854.
   PubMed Web of Science ®Google Scholar
• Koblizek V, Chlumsky J, Zindr V, et al. Chronic Obstructive Pulmonary Disease: official diagnosis and treatment guidelines of the Czech Pneumological and Phthisiological Society; a novel phenotypic approach to COPD with patient-oriented care. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2013;157:189–201 PMID:23733084.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Soler-Cataluna JJ, Calle M, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase. Arch Bronconeumol. 2017;53:324–335. doi:10.1016/j.arbres.2017.03.018. PMID:28477954.
   PubMed Web of Science ®Google Scholar
• Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. doi:10.1164/rccm.201204-0596PP. PMID:22878278.
   PubMed Web of Science ®Google Scholar
• Chen D, Restrepo MI, Fine MJ, et al. Observational study of inhaled corticosteroids on outcomes for COPD patients with pneumonia. Am J Respir Crit Care Med. 2011;184:312–316. doi:10.1164/rccm.201012-2070OC. PMID:21512168.
   PubMed Web of Science ®Google Scholar
• Bourbeau J, Aaron SD, Barnes NC, et al. Evaluating the risk of pneumonia with inhaled corticosteroids in COPD: Retrospective database studies have their limitations SA. Respir Med. 2017;123:94–97. doi:10.1016/j.rmed.2016.12.015. PMID:28137503.
   PubMedGoogle Scholar
• Festic E, Scanlon PD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2015;191:141–148. doi:10.1164/rccm.201409-1654PP. PMID:25409118.
   PubMed Web of Science ®Google Scholar
• Miravitlles M, Vogelmeier C, Roche N, et al. A review of national guidelines for management of COPD in Europe. Eur Respir J. 2016;47:625–637. doi:10.1183/13993003.01170-2015. PMID:26797035.
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365:689–698. doi:10.1056/NEJMoa1104623. PMID:21864166.
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med. 2008;178:1139–1147. doi:10.1164/rccm.200801-145OC. PMID:18723437.
   PubMed Web of Science ®Google Scholar
• Suresh Babu K, Kastelik J, Morjaria JB. Role of long term antibiotics in chronic respiratory diseases. Respir Med. 2013;107:800–815. doi:10.1016/j.rmed.2013.02.009. PMID:23522403.
   PubMedGoogle Scholar
• Miravitlles M. What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved? Arch Bronconeumol. 2016;52:1–2 doi:10.1016/j.arbres.2015.04.001. PMID:26026686.
   PubMed Web of Science ®Google Scholar